Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults

NCT06842173 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

700

Enrollment

OTHER_GOV

Sponsor class

Conditions

Avian Influenza A Virus

Interventions

BIOLOGICAL: Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted) 7.5 mcg
BIOLOGICAL: Monovalent influenza vaccine type A (H5N8) 15 mcg
OTHER: Placebo

Sponsor

Butantan Institute

Collaborators

[object Object]